83 results about "Leucine-rich repeat" patented technology

The present invention relates to novel compounds of formula (I)that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and / or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.

Compositions, systems and methods are provided for conferring disease resistance to plant pathogens that use proteases to target plant substrate proteins inside plant cells. Briefly, the compositions, systems and methods are based upon plant substrate proteins that are targeted by pathogen-specific proteases and that activate nucleotide binding site-leucine rich repeat (NB-LRR) disease resistance proteins when cleaved by the protease. These substrate proteins are modified such that the endogenous protease recognition sequence is replaced by a protease recognition sequence specific to a different pathogen protease (i.e., a heterologous protease recognition sequence). The modified plant substrate protein therefore can be used in connection with its corresponding NB-LRR protein to activate resistance in response to cleavage by the heterologous pathogen-specific protease. When activated by the plant pathogen-specific protease, the pair initiates host defense responses thereto, including programmed cell death.

The present invention concerns a method for improving the growth characteristics of plants by increasing expression of at least part of a Leucine Rich Repeat Receptor-Like Kinase (RKS11, RKS4 or an orthologue of these). One such method comprises introducing into a plant a nucleic acid encoding at least part of a Leucine Rich Repeat Receptor-Like Kinase (RKS11 or RKS4 or an orthologue thereof). The invention also relates to transgenic plants having introduced therein a nucleic acid or variant thereof encoding at least part of a Leucine Rich Repeat Receptor-Like Kinase (RKS11 or RKS4 or an orthologue thereof), which plants have improved growth characteristics relative to corresponding wild type plants. The present invention also concerns constructs useful in the methods of the invention.

The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and / or prevention of various diseases and / or disorders related to these polypeptides, particularly gastrointestinal diseases and / or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

The present disclosure relates to the isolation of a novel reagent selected for its binding characteristics to the proteins internalin B or internalin A. InIB is a surface-localized protein of Listeria monocytogenes that binds and activates the receptor tyrosine kinase Met. InIB promotes invasion of a number of cells including hepatocytes, endothelial and epithelial cell lines and causes activation of the actin-mediated internalization of the bacterium. InIA belongs to a large group of surface-localized leucine-rich repeat (LRR) proteins identified in the Listeria genome. InIA enables Listeria monocytogenes to invade non-phagocytic cells such as those of the human intestinal epithelium and is sufficient for adhesion to and inducing uptake into epithelial cells. The disclosed nucleic acid ligands to internalin B and internalin A may be useful for determining the presence or absence of internalin B, internalin A, or Listeria in food, clinical or environmental samples; they may also be useful as an agent for combating Listeria infection by binding to and inactivating the infection-promoting inlB or inlA proteins. One object is to incorporate these nucleic acid ligands into an in vitro diagnostic or biosensor platform designed to detect the presence or absence of internalin B, internalin A, or Listeria in food, clinical or environmental samples. Another object is to employ these nucleic acid ligands in methods for treating or preventing Listeria infection.

The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

The invention relates to a sequence and functional application of an LRR (Leucine-Rich Repeat) acceptor protein kinase gene NtRLK2 related to the resistance of tobacco to bacterial wilt, and belongs to the technical field of molecular biology. According to the sequence and the functional application, through the analysis of a gene chip, a partial segment of one LRR acceptor protein kinase gene NtRLK2 of which the expression is up-regulated by 2 times when being induced by ralstonia solanacearum is obtained; a full-length cDNA (complementary Deoxyribonucleic Acid) sequence of the LRR acceptor protein kinase gene NtRLK2 is obtained through an RACE (Rapid Amplification of cDNA end) technique; the gene is cloned from a high-bacterial-wilt-resistance variety line 3 of the tobacco, is used for constructing over-expression and RNAi (Ribonucleic Acid interference) expression vectors, and is transferred into a bacterial wilt infected variety Cuibi 1# in the tobacco; indicated by inoculation identification, the RANi of the gene obviously enhances the disease resistance of a tobacco plant to the bacterial wilt; preliminarily predicted, the gene is possibly an interacting gene of an endogenous disease-resistant gene; the expression of the disease-resistant gene is inhibited. According to the application, a foundation is about to be laid for the bacterial-wilt disease-resistant genetic breeding of the tobacco.

The invention discloses a transmembrane protein gene triticum asetivum leucine rich repeat 3 (TaLRR3) with a leucine rich repeat (LRR) structure domain as well as an expression vector and an application thereof and belongs to the field of gene engineering. The complementary deoxyribonucleic acid (cDNA) sequence of the transmembrane protein gene TaLRR3 with the LRR structure domain is SEQ ID NO.1,and the coded amino acid sequence is SEQ ID NO.2. The gene is from ordinary wheat (Triticum asetivum L.) 92R137 and is reported in the wheat for the first time. The TaLRR3 is induced by stripe rust in a stripe rust resistant wheat variety 92R137, the expression is enhanced, and in addition, the expression level is much higher than the expression level in the disease susceptible variety Yangmai 158. The gene is inserted into pBI220 to obtain an over-expression vector, in addition, the susceptible stripe rust wheat variety Yangmai 158 is converted, and T0-generation stripe rust qualification results show that the over-expression of the TaLRR3 can improve the stripe rust resistance of the susceptible stripe rust wheat variety.

Two types of compositions having an eye-drop delivery system are used during or after an orthokeratology procedure to prevent or retard relaxation of corneal tissue back to the original anterior curvature of the cornea. Each composition functions independently from the others and is a different approach of preparing a stabilizing agent. The first composition is directed to a biologically compatible composition comprising fibril associated collagens with interrupted triple helices (FACITs) and / or small leucine-rich repeat proteoglycans (SLRPs). The fibril associated collagen family includes various types of collagens, such as type VI, type XX, type XII, and type XIV. The small leucine-rich repeat proteoglycans family includes decorin, keratocan, biglycan, epiphycan, lumican, mimecan, and fibromodulin. The second composition includes the enzyme found as a normal component of tissues, plasma, or epidermis, such as transglutaminase.

The invention discloses a gene marker for detecting esophageal cancer and a use thereof and a detection method. The gene marker comprises one or more of genes of a phospholipid inositol phosphatase CXdomain containing protein 3, a sulfatase 1, a F-Box and leucine-rich repeat protein 7, a Tolloid-like protein 1, a RNA binding template single-stranded function protein 3, an ADAMTS-like protein 1, phosphodiesterase 10A, a LIM-domain ligase 2, a gamma-aminobutyric acid type A receptor protein in the gamma 3 subfamily and a sequence similar 155 family protein A. The gene marker is used for detecting esophageal cancer. The gene marker is suitable for a more extensive source of DNA samples, the detection is safe and non-invasive, the asymptomatic people have high acceptance to detection, the accuracy is high, the gene marker has high sensitivity and specificity to the early esophageal cancer, the operation is convenient, the user experience is good and the dynamic monitoring of the recurrence and metastasis of esophageal cancer is easy.

The invention discloses application of a chlamydomonas reinhardtii LRR (Leucine Rich Repeat) gene in regulating and controlling cadmium resistance of chlamydomonas reinhardtii, and belongs to the technical field of biologics and the field of environmental pollution improvement. According to the application, an aphVIII fragment with a paromomycin resistance gene is randomly inserted into chlamydomonas, then a chlamydomonas reinhardtii mutant alga strain which is remarkable in cadmium chloride resistance is cultured, and further identification shows that the cadmium sensitivity of the mutant alga strain is caused since the aphVIII (SEQ ID NO:3) fragment is inserted into an LRR gene (a CDS (Cadmium Sulfide) sequence is shown in SEQ ID NO:1 in the specification). By reducing expression of thechlamydomonas reinhardtii LRR gene, deactivating the LRR gene or by deleting the LRR gene, the cadmium resistance of the chlamydomonas reinhardtii can be improved; a cadmium resistance improved chlamydomonas reinhardtii strain obtained by means of genetic engineering can be applied to monitoring and improvement of cadmium polluted water areas, cadmium polluted water environments can be treated with the cadmium resistance improved chlamydomonas reinhardtii strain, the operation is simple and feasible, and the cost is low.

The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.